Oral Step-Down Noninferior for Severe Pediatric CAP

Key Takeaways

• In hospitalized young children with severe CAP in sub-Saharan Africa, oral step-down after at least 24 hours of IV antibiotics was reported as noninferior to completing 5 days of IV therapy.
• At 28 days, investigators reported no significant differences in death or readmission among the assigned treatment groups.
• Co-amoxiclav showed no evidence of superiority over amoxicillin alone as oral step-down therapy.
• Oral courses of 4 and 5 days were reported as not inferior to 8-day oral courses.

Severe community-acquired pneumonia (CAP) remains a common reason for hospitalization in young children, and current World Health Organization (WHO) guidance recommends 5 days of intravenous (IV) antibiotics for severe disease. Once a child is clinically improving, however, it remains uncertain whether IV treatment must continue, whether oral amoxicillin is sufficient for step-down therapy, and how long total treatment needs to last. Investigators examined those questions in hospitalized children across sub-Saharan Africa.

In the open-label, parallel-group PediCAP trial in The Lancet, investigators enrolled 1,101 hospitalized children aged 2 months to 6 years at 13 hospitals in sub-Saharan Africa. They assigned 100 to 5 days of IV antibiotics, 502 to oral amoxicillin step-down after at least 24 hours of IV therapy, and 499 to oral amoxicillin-clavulanate step-down after that initial IV period. Children in the oral groups were divided evenly across oral durations of 4 to 8 days, and switching was allowed only when the treating clinician judged that a child had clinically improved. Median IV treatment before switch was 2 days in both oral groups.

At 28-day follow-up, investigators reported that oral step-down was noninferior to completing the full 5-day IV course, although the available source summary did not provide detailed effect estimates. Death and readmission did not differ significantly among groups. Investigators also reported no evidence that co-amoxiclav was superior to amoxicillin alone and that oral courses of 4 and 5 days were not inferior to 8-day oral courses.

This trial was conducted at hospitals in sub-Saharan Africa, so the findings speak most directly to that care setting rather than automatically to inpatient practice in North America. The enrolled population excluded children who required immediate intensive care, and relatively few participants had HIV, severe malnutrition, or other complicating conditions. The authors linked early oral step-down to potential reductions in hospital stay and antibiotic exposure, but those were interpretive implications rather than measured outcomes.

The PediCAP investigators reported that clinically improving young children hospitalized with severe CAP had noninferior outcomes with early oral step-down versus continued IV completion, with no apparent advantage for amoxicillin-clavulanate and no apparent penalty for the shorter oral courses tested.

Clinician Questions

Which children with severe community-acquired pneumonia were represented in PediCAP?

PediCAP represented hospitalized children aged 2 months to 6 years with severe community-acquired pneumonia treated at 13 hospitals in sub-Saharan Africa. Applicability is narrower for children needing immediate intensive care and for higher-risk groups because those children were excluded or only sparsely represented.

When were children switched from IV to oral antibiotics in PediCAP?

Step-down was permitted only after at least 24 hours of IV antibiotics and only when the treating clinician judged the child clinically improved. In practice, children assigned to oral therapy switched after a short IV course, with a median of 2 days before transition.

Did oral step-down outcomes differ between amoxicillin and amoxicillin-clavulanate in severe pediatric CAP?

Investigators reported no evidence of superiority for co-amoxiclav over amoxicillin alone as oral step-down therapy in hospitalized young children with severe community-acquired pneumonia.